Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Michigan Institute of Urology, P.C.
mi
from
Troy, MI
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Michigan Institute of Urology, P.C.
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Delaware Valley Urology, LLC Burlington
mi
from
Mount Laurel, NJ
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Delaware Valley Urology, LLC Burlington
mi
from
Mount Laurel, NJ
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Delaware Valley Urology, LLC
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Urologic Consultants of SE PA
mi
from
Bala-Cynwyd, PA
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Urologic Consultants of SE PA
mi
from
Bala-Cynwyd, PA
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Ilumina Clinical Associates
mi
from
Indiana, PA
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Ilumina Clinical Associates
mi
from
Indiana, PA
Click here to add this to my saved trials
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated:  8/23/2017
Southern Interior Medical Research Inc.
mi
from
Kelowna,
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer
A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Enrolling
Updated: 8/23/2017
Southern Interior Medical Research Inc.
mi
from
Kelowna,
Click here to add this to my saved trials
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Status: Enrolling
Updated:  8/24/2017
Fort Jackson Advance Individual Training Units
mi
from
Columbia, SC
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Preventing Health Damaging Behaviors in Male and Female Army Recruits
Status: Enrolling
Updated: 8/24/2017
Fort Jackson Advance Individual Training Units
mi
from
Columbia, SC
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of California
mi
from
San Diego, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of California
mi
from
San Diego, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Florida College of Medicine (Shands)
mi
from
Gainesville, FL
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
The Johns Hopkins SKCCC
mi
from
Baltimore, MD
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
DFCI/Brigham & Women's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Duke University Medical Center (peds)
mi
from
Durham, NC
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Duke University Medical Center (peds)
mi
from
Durham, NC
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University Hospitals of Cleveland/Case Western
mi
from
Cleveland, OH
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
University of Texas, MD Anderson CRC
mi
from
Houston, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated:  8/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)
Status: Enrolling
Updated: 8/24/2017
Washington University/ Barnes-Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Status: Enrolling
Updated:  8/24/2017
CUNY
mi
from
New York, NY
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation
Status: Enrolling
Updated: 8/24/2017
CUNY
mi
from
New York, NY
Click here to add this to my saved trials
Targeting Platelets in Chronic HIV Infection
Targeting Platelets in Chronic HIV Infection
Status: Enrolling
Updated:  8/28/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Targeting Platelets in Chronic HIV Infection
Targeting Platelets in Chronic HIV Infection
Status: Enrolling
Updated: 8/28/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated:  8/28/2017
University of New England College of Osteopathic Medicine
mi
from
Biddeford, ME
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated: 8/28/2017
University of New England College of Osteopathic Medicine
mi
from
Biddeford, ME
Click here to add this to my saved trials
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated:  8/28/2017
West Virginia School of Osteopathic Medicine
mi
from
Lewisburg, WV
Osteopathic Otitis Media Research Study
Effect of Osteopathic Manipulative Medicine (OMM) on the Duration of Middle Ear Effusion in Children Following Diagnosis of Acute Otitis Media, as Measured by Tympanograms and Acoustic Reflectometry
Status: Enrolling
Updated: 8/28/2017
West Virginia School of Osteopathic Medicine
mi
from
Lewisburg, WV
Click here to add this to my saved trials
Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes
TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"
Status: Enrolling
Updated:  8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes
TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"
Status: Enrolling
Updated: 8/28/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Anaheim, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Carmichael, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Carmichael, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Fair Oaks, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Fair Oaks, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Sacramento, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
San Diego, CA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Boynton Beach, FL
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Indianapolis, IN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
South Bend, IN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
South Bend, IN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Portage, MI
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Portage, MI
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
New York, NY
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Tulsa, OK
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Portland, OR
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Philadelphia, PA
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Memphis, TN
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated:  8/28/2017
GSK Investigational Site
mi
from
Saint Petersburg, FL
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
The Effect of Valacyclovir 1g Once Daily on HSV-2 Viral Shedding in Subjects Newly Diagnosed With Genital Herpes Infection
Status: Enrolling
Updated: 8/28/2017
GSK Investigational Site
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated:  8/29/2017
Melinta Investigational Site
mi
from
Montgomery, AL
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections
Status: Enrolling
Updated: 8/29/2017
Melinta Investigational Site
mi
from
Montgomery, AL
Click here to add this to my saved trials